Abstract:

Ｏｂｊｅｃｔｉｖｅ：Lipoprotein glomerulopathy is a rare inherited disease caused by the abnormal metabolism of Apolipoprotein E (ApoE). The objective of this study is to retrospectively observe the effect of fenofibrate in Chinese patients with lipoprotein glomerulopathy (LPG).
Ｍｅｔｈｏｄｏｌｏｇｙ：From 2003 to 2013, thirty patients were diagnosed as LPG in our hospital and were followed up for more than 2 years. Patients who received fenofibrate at a dose of 200-400 mg/d for at least 24 months were assigned to Brate group (n=15), and patients who didnt recieve fenofibrate were assigned to control group (n=15).
Ｒｅｓｕｌｔｓ：（1）Baseline: The baseline parameters including serum creatinine, albumin, ApoE levels and urine protein between two groups were not significantly different(P＞005). (2)Clinical effect: After 24 months treatment, lipid profiles, proteinuria, and serum albumin were improved in Brate group. In Brate group, the urinary albumin was lower after 12 to 24 months treatment, serum creatinine was decreased slightly, and serum albumin was increased. However, the posttreatment parameters were deteriorated in the control group. (3)Prognosis: In Brate group, 11 patients (733%) reached remission (complete plus partial remission), and 3 patients (200%) presented with a doubling of serum creatinine. In control group, only one (66%) reached complete remission, and 11 patients (733%) were a doubling of serum creatinine. Survival analysis showed that the median time to doubling of serum creatinine was 716 vs 348 months in Brate group and control group (P<005).
Ｃｏｎｃｌｕｓｉｏｎ：Fenofibrate can induce remission of lipoprotein glomerulopathy and decelerate the progress of renal insufficiency.